Bruce & Co. Inc. Cuts Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Bruce & Co. Inc. reduced its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 16.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 250,000 shares of the company’s stock after selling 50,000 shares during the period. Bruce & Co. Inc. owned about 0.28% of Caribou Biosciences worth $398,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in CRBU. Milestone Asset Management LLC grew its holdings in shares of Caribou Biosciences by 5.6% during the 4th quarter. Milestone Asset Management LLC now owns 163,789 shares of the company’s stock valued at $260,000 after purchasing an additional 8,662 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in Caribou Biosciences during the third quarter valued at about $28,000. Intech Investment Management LLC grew its stake in shares of Caribou Biosciences by 69.4% during the fourth quarter. Intech Investment Management LLC now owns 37,478 shares of the company’s stock valued at $60,000 after buying an additional 15,352 shares during the last quarter. US Bancorp DE grew its stake in shares of Caribou Biosciences by 3,524.2% during the fourth quarter. US Bancorp DE now owns 27,218 shares of the company’s stock valued at $43,000 after buying an additional 26,467 shares during the last quarter. Finally, Thrive Wealth Management LLC purchased a new position in shares of Caribou Biosciences in the fourth quarter worth about $51,000. 77.51% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a report on Wednesday. Citigroup dropped their price objective on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Finally, Bank of America decreased their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Caribou Biosciences has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Price Performance

CRBU opened at $1.00 on Friday. Caribou Biosciences, Inc. has a one year low of $0.95 and a one year high of $5.77. The business has a 50 day simple moving average of $1.30 and a two-hundred day simple moving average of $1.75. The firm has a market capitalization of $93.00 million, a price-to-earnings ratio of -0.61 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $2.08 million for the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. As a group, sell-side analysts expect that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.